DULUTH, Ga., May 11, 2026 /PRNewswire/ -- Bridge to Life™ Ltd., a global innovator in organ preservation solutions and perfusion technology, today announced new data from studies using Hypothermic Oxygenated Perfusion (HOPE) for the preservation of donor livers awaiting transplantation. The studies collectively demonstrate that HOPE with VitaSmart™ improves utilization of steatotic, older, and previously discarded donor livers, while preserving mitochondrial function and supporting flavin mononucleotide (FMN) as a direct biomarker of graft viability. Together, these findings strengthen the clinical and economic case for broader adoption of HOPE across transplant centers in the U.S. and Europe.
"FDA clearance of VitaSmart™ established Bridge to Life as the first company to bring HOPE to the U.S. market as a cleared platform for liver transplantation. These new ILTS data reinforce that HOPE is not simply a preservation strategy—it is a tool for organ recovery, viability assessment, and better transplant decision-making," said Don Webber, president and CEO of Bridge to Life Ltd. "By extending the use of marginal donor organs and preserving mitochondrial integrity, we are helping transplant teams move from preservation toward precision transplantation."
Bridge to Life™ Ltd is a global innovator of organ preservation technologies and solutions, offering premier products such as Belzer UW, EasiSlush and the . With a strong focus on product quality, innovation and accessibility, the company serves and partners with leading Transplant Centers and Organ Procurement Organizations globally.
Logo -
View original content: https://www.prnewswire.co.uk/news-releases/bridge-to-life-presents-new-ilts-2026-data-showing-vitasmart-hypothermic-oxygenated-perfusion-hope-expands-use-of-marginal-donor-livers-and-preserves-mitochondrial-function-for-real-time-viability-assessment-302767520.html